Oncopeptides’ $58.7 Million Shares Offering

White & Case LLP has advised the Joint Bookrunners, Jefferies International Limited, Carnegie Investment Bank AB (publ) and DNB Markets, a part of DNB Bank ASA, on the deal.

The board of directors of Oncopeptides resolved on a directed share issue of 4,750,000 new shares at a subscription price of SEK 115 per share which means that the Company will receive gross proceeds of approximately SEK 546 million. The subscription price in the Issue was determined through an accelerated bookbuild procedure.

Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company was established in 2000 and is based in Stockholm, Sweden.

The White & Case team which advised on the transaction was led by partner Rikard Stenberg (Stockholm) and included partner Mikko Hulkko (Helsinki), with support from associate Gustaf Wiklund (Stockholm).

Involved fees earner: Mikko Hulkko – White & Case; Rikard Stenberg – White & Case; Gustaf Wiklund – White & Case;

Law Firms: White & Case;

Clients: Carnegie; DNB Bank ASA; DNB Markets; Jefferies;